Collectively, these findings demonstrate that CldU and PARPi act synergistically in BRCA2-mutant cancer cells, even in the context of acquired PARP inhibitor resistance, including resistance mediated by BRCA2 reversion mutations. The gene discussed is PARP1; the disease is cancer.